Dongwu Securities released a research report on April 17 stating that it gave Jichuan Pharmaceutical (600566.SH) a purchase rating. The main reasons for the rating include: 1) the accelerated release of Q4 profits, which are expected to maintain high profit margins in 2024; 2) the cost ratio is well controlled to accelerate the release of profits; 3) the release of a new round of equity incentive plans. (Mainichi Keizai Shimbun)
东吴证券4月17日发布研报称，给予济川药业（600566.SH）买入评级。评级理由主要包括：1）Q4利润加速释放，2024年有望维持高利润率；2）费用率控制良好，加速释放利润；3）发布新一轮股权激励计划。（每日经济新闻）
Dongwu Securities released a research report on April 17 stating that it gave Jichuan Pharmaceutical (600566.SH) a purchase rating. The main reasons for the rating include: 1) the accelerated release of Q4 profits, which are expected to maintain high prof
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.